More Signs of Life for Obesity Drugs (VVUS, OREX, ARNA)
VIVUS Inc. (NASDAQ: VVUS) is getting yet one more sign of life for its Qnexa drug aimed at treating obesity. The emerging drug outfit has reached an agreement with the FDA on resubmitting its new drug...
View ArticlePrivate Equity Changes CRO Landscape With PPD Buyout (PPDI, CRL, CVD, PRXL)
The world of contract research organizations is changing. The unexpected news hit the wire this Monday that Pharmaceutical Product Development, Inc. (NASDAQ: PPDI) is being acquired. This was no...
View ArticleUnusual Analyst Upgrade & Endorsement for Cell Therapeutics (CTIC)
Cell Therapeutics, Inc. (NASDAQ: CTIC) is a controversial stock in the field of cancer and the company is still aiming for a 2012 debut market launch for its pixantrone drug candidate. In the last...
View ArticleOdds-Making on a Human Genome Sciences Acquisition (HGSI, GSK, BIIB, MRK)
Human Genome Sciences Inc. (NASDAQ: HGSI) is surging on reports that GlaxoSmithKline PLC (NYSE: GSK) could be set to make a $25.00 per share offer to acquire the company. The report surfaced in the...
View ArticleTop Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ,...
Earnings season is afoot and we wanted to see how the analysts are ranking the top biotech stocks before these companies begin their earnings reports. We pulled the top biotech and biohealth related...
View ArticleRare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
Vical Inc. (NASDAQ: VICL) and VIVUS, Inc. (NASDAQ: VVUS) are both running higher this Friday on news that Credit Suisse initiated both biotech outfits with “Outperform” ratings. What matters more than...
View ArticleImplosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
Tuesday has been an awful day for shareholders of Targacept Inc. (NASDAQ: TRGT). The company shares lost more than half of their value on news that initial test results from the Phase III...
View ArticleAlimera Implosion Analysis, What Is Next (ALIM, PSDV)
Alimera Sciences, Inc. (NASDAQ: ALIM) is the latest of the drug implosions and this one looks even worse than just severely damaging. The FDA’s complete response letter is really a request for...
View ArticleCan Human Genome Really Double Its Stock Price? (HGSI)
At the end of December, we usually review the biotech sector to see which stocks have the most upside for the year ahead. The basis of the “implied upside” is the consensus mean estimate from Thomson...
View ArticleShouldn’t VIVUS Raise Capital Now? (VVUS)
While we have started mostly using The Wire at 247wallst.com for our biotech and active trader posts (among many other aspects 50 to 100 times per day), we have a question for BioHealthInvestor readers...
View Article
